Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Heron Therapeutics (HRTX)

Heron Therapeutics (HRTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,327,392
  • Shares Outstanding, K 90,855
  • Annual Sales, $ 145,970 K
  • Annual Income, $ -204,750 K
  • 60-Month Beta 1.79
  • Price/Sales 9.07
  • Price/Cash Flow N/A
  • Price/Book 4.09

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.61
  • Number of Estimates 5
  • High Estimate -0.51
  • Low Estimate -0.75
  • Prior Year -0.42
  • Growth Rate Est. (year over year) -45.24%

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.13 +18.13%
on 09/04/20
16.48 -5.86%
on 09/17/20
+1.31 (+9.23%)
since 08/28/20
3-Month
12.52 +23.88%
on 06/29/20
18.18 -14.69%
on 07/20/20
-4.31 (-21.75%)
since 06/26/20
52-Week
9.60 +61.56%
on 03/16/20
26.81 -42.15%
on 12/04/19
-4.09 (-20.87%)
since 09/27/19

Most Recent Stories

More News
Heron Therapeutics Receives European Commission Authorization for ZYNRELEF™ (HTX-011) for the Treatment of Postoperative Pain

, /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of...

HRTX : 14.77 (+1.10%)
Heron Therapeutics Announces Publication of Results from EPOCH 2 Follow-On Study, a Phase 2b Study of HTX-011 in Patients Undergoing Hernia Repair Surgery

, /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of...

HRTX : 14.77 (+1.10%)
Heron Therapeutics to Present at Cantor Virtual Global Healthcare Conference

, /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of...

HRTX : 14.77 (+1.10%)
Biotech Stock Roundup: GILD Submits BLA, ALBO Gains on Study Data & More

The biotech sector remains in focus with regulatory and other pipeline updates.

GILD : 63.04 (+1.27%)
AMRN : 3.96 (+3.94%)
AKBA : 2.49 (+0.40%)
HRTX : 14.77 (+1.10%)
ALBO : 33.22 (-0.27%)
Heron Therapeutics Announces Successful Outcome of FDA Type A Meeting to Discuss HTX-011 for the Management of Postoperative Pain

, /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of...

HRTX : 14.77 (+1.10%)
Interesting HRTX Put And Call Options For October 16th

Investors in Heron Therapeutics Inc saw new options begin trading this week, for the October 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the HRTX options...

HRTX : 14.77 (+1.10%)
Heron Therapeutics (HRTX) Reports Q2 Loss, Tops Revenue Estimates

Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -3.39% and 38.64%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

HRTX : 14.77 (+1.10%)
Heron Therapeutics: 2Q Earnings Snapshot

SAN DIEGO (AP) _ Heron Therapeutics Inc. (HRTX) on Wednesday reported a loss of $55.2 million in its second quarter.

HRTX : 14.77 (+1.10%)
Heron Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2020 and Highlights Recent Corporate Updates

, /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best–in-class treatments to address some...

HRTX : 14.77 (+1.10%)
Heron Therapeuti Rises 1.99% on Heavy Volume: Watch For Potential Pullback

Heron Therapeuti (NASDAQ:HRTX) traded in a range yesterday that spanned from a low of $19.76 to a high of $20.10. Yesterday, the shares gained 2.0%, which took the trading range above the 3-day high...

HRTX : 14.77 (+1.10%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade HRTX with:

Business Summary

Heron Therapeutics Inc. is a specialty pharmaceutical company. The company is developing products using its proprietary Biochronomer (TM) polymer-based drug delivery platform. Its product portfolio includes APF530, is being developed for the prevention of acute chemotherapy-induced nausea and vomiting....

See More

Key Turning Points

2nd Resistance Point 15.09
1st Resistance Point 14.85
Last Price 14.77
1st Support Level 14.36
2nd Support Level 14.11

See More

52-Week High 26.81
Fibonacci 61.8% 20.24
Fibonacci 50% 18.20
Fibonacci 38.2% 16.17
Last Price 14.77
52-Week Low 9.60

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar